RU2709205C2 - Замещенные ароматические соединения и фармацевтические композиции для предотвращения и лечения остеопороза - Google Patents

Замещенные ароматические соединения и фармацевтические композиции для предотвращения и лечения остеопороза Download PDF

Info

Publication number
RU2709205C2
RU2709205C2 RU2017116178A RU2017116178A RU2709205C2 RU 2709205 C2 RU2709205 C2 RU 2709205C2 RU 2017116178 A RU2017116178 A RU 2017116178A RU 2017116178 A RU2017116178 A RU 2017116178A RU 2709205 C2 RU2709205 C2 RU 2709205C2
Authority
RU
Russia
Prior art keywords
osteoporosis
compound
use according
bone
alkyl
Prior art date
Application number
RU2017116178A
Other languages
English (en)
Russian (ru)
Other versions
RU2017116178A (ru
RU2017116178A3 (enExample
Inventor
Лин Ганьон
Брижит Груа
Original Assignee
Прометик Фарма Смт Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Прометик Фарма Смт Лимитед filed Critical Прометик Фарма Смт Лимитед
Publication of RU2017116178A publication Critical patent/RU2017116178A/ru
Publication of RU2017116178A3 publication Critical patent/RU2017116178A3/ru
Application granted granted Critical
Publication of RU2709205C2 publication Critical patent/RU2709205C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32—Phenylacetic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2017116178A 2014-10-10 2015-10-08 Замещенные ароматические соединения и фармацевтические композиции для предотвращения и лечения остеопороза RU2709205C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462062597P 2014-10-10 2014-10-10
US62/062,597 2014-10-10
PCT/CA2015/000540 WO2016054728A1 (en) 2014-10-10 2015-10-08 Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis

Publications (3)

Publication Number Publication Date
RU2017116178A RU2017116178A (ru) 2018-11-19
RU2017116178A3 RU2017116178A3 (enExample) 2019-05-16
RU2709205C2 true RU2709205C2 (ru) 2019-12-17

Family

ID=55652429

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017116178A RU2709205C2 (ru) 2014-10-10 2015-10-08 Замещенные ароматические соединения и фармацевтические композиции для предотвращения и лечения остеопороза

Country Status (23)

Country Link
US (2) US20180228750A1 (enExample)
EP (1) EP3203999B1 (enExample)
JP (1) JP6700639B2 (enExample)
KR (1) KR20170066476A (enExample)
CN (1) CN106999456B (enExample)
AR (1) AR102246A1 (enExample)
AU (1) AU2015330645B2 (enExample)
BR (1) BR112017007426A2 (enExample)
CA (1) CA2963354A1 (enExample)
DK (1) DK3203999T3 (enExample)
ES (1) ES2785317T3 (enExample)
IL (1) IL251404B (enExample)
MX (1) MX376873B (enExample)
MY (1) MY194308A (enExample)
PH (1) PH12017500638A1 (enExample)
PL (1) PL3203999T3 (enExample)
PT (1) PT3203999T (enExample)
RU (1) RU2709205C2 (enExample)
SG (1) SG11201702868VA (enExample)
TW (1) TWI699200B (enExample)
UY (1) UY36356A (enExample)
WO (1) WO2016054728A1 (enExample)
ZA (1) ZA201702639B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016054725A1 (en) * 2014-10-10 2016-04-14 Prometic Biosciences Inc. Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
AU2015345943B2 (en) * 2014-11-12 2020-03-19 Liminal Biosciences Limited Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
KR20190065252A (ko) * 2016-08-18 2019-06-11 인테크린 테라퓨틱스, 아이엔씨. 골 질환 치료용 PPARγ 작용제
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
AU2021356346A1 (en) * 2020-10-06 2023-06-15 Pharmaceutique Ingenew Inc. Substituted aromatic compounds and pharmaceutical compositions thereof
MX2024005982A (es) * 2021-11-17 2024-05-30 Natreon Inc Withania somnifera y asparagus racemosus en el tratamiento de enfermedades posmenopausicas.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006124662A1 (en) * 2005-05-13 2006-11-23 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
WO2012055014A1 (en) * 2010-10-27 2012-05-03 Prometic Biosciences Inc. Phenylketone carboxylate compounds and pharmaceutical uses thereof
WO2012097427A1 (en) * 2010-10-27 2012-07-26 Prometic Biosciences Inc. Compounds and compositions for the treatment of cancer
WO2014138907A1 (en) * 2013-03-15 2014-09-18 Prometic Biosciences Inc. Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis
WO2014138906A1 (en) * 2013-03-15 2014-09-18 Prometic Biosciences Inc. Substituted aromatic compounds and related method for the treatment of fibrosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2427416B1 (en) * 2009-05-04 2016-03-09 Prometic Pharma Smt Limited Substituted aromatic compounds and pharmaceutical uses thereof
BRPI1015118A2 (pt) * 2009-05-04 2016-04-12 Prometic Biosciences Inc sais de ácido pentilfenilacético e usos farmacêuticos dos mesmos
WO2016054725A1 (en) * 2014-10-10 2016-04-14 Prometic Biosciences Inc. Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006124662A1 (en) * 2005-05-13 2006-11-23 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
WO2012055014A1 (en) * 2010-10-27 2012-05-03 Prometic Biosciences Inc. Phenylketone carboxylate compounds and pharmaceutical uses thereof
WO2012097427A1 (en) * 2010-10-27 2012-07-26 Prometic Biosciences Inc. Compounds and compositions for the treatment of cancer
WO2014138907A1 (en) * 2013-03-15 2014-09-18 Prometic Biosciences Inc. Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis
WO2014138906A1 (en) * 2013-03-15 2014-09-18 Prometic Biosciences Inc. Substituted aromatic compounds and related method for the treatment of fibrosis

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
. LABOUESSE MA. et al. Associations among endocrine, inflammatory, and bone markers, body composition and weight loss induced bone loss. Bone 64 (2014): 138-46. Available online 4 April 2014, реферат, с.141, 1-я колонка, 3-й абзац, с.144, 1-я колонка. *
CELSO MARTINS QUEIROZ-JUNIOR et al. A Controversial role for IL-12 in immune response and bone resorption at apical periodontal sites. Clinical and developmental immunology. Vol. 2010. Accepted 22.12.2010, реферат, фиг.1 *
CELSO MARTINS QUEIROZ-JUNIOR et al. A Controversial role for IL-12 in immune response and bone resorption at apical periodontal sites. Clinical and developmental immunology. Vol. 2010. Accepted 22.12.2010, реферат, фиг.1. *
WANG Yue et al. Puerarin stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK/ERK and PI3K/Akt activation. Phytomedicine. 20 (2013), 787-796, с.790, глава Результаты, с.793, 2 колонка. *
WANG Yue et al. Puerarin stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK/ERK and PI3K/Akt activation. Phytomedicine. 20 (2013), 787-796, с.790, глава Результаты, с.793, 2 колонка. LABOUESSE MA. et al. Associations among endocrine, inflammatory, and bone markers, body composition and weight loss induced bone loss. Bone 64 (2014): 138-46. Available online 4 April 2014, реферат, с.141, 1-я колонка, 3-й абзац, с.144, 1-я колонка. ЭНЦИКЛОПЕДИЯ ЛЕКАРСТВ. М., РЛС, 2001, 8-е изд., с.1346, раздел М80 - с.1347, раздел М82.8. *
ШОСТАК Н.А. и др. Ревматоидный артрит и остеопороз. РМЖ N5 от 06.03.2004, с.287 [он лайн] [найдено 25.04.2019] (найдено из интернет: www.rmj.ru). *
ЭНЦИКЛОПЕДИЯ ЛЕКАРСТВ. М., РЛС, 2001, 8-е изд., с.1346, раздел М80 - с.1347, раздел М82.8. *

Also Published As

Publication number Publication date
AR102246A1 (es) 2017-02-15
KR20170066476A (ko) 2017-06-14
BR112017007426A2 (pt) 2018-01-16
CA2963354A1 (en) 2016-04-14
MY194308A (en) 2022-11-27
TW201618762A (zh) 2016-06-01
IL251404B (en) 2020-11-30
WO2016054728A1 (en) 2016-04-14
IL251404A0 (en) 2017-05-29
PT3203999T (pt) 2020-04-23
EP3203999B1 (en) 2020-01-08
RU2017116178A (ru) 2018-11-19
DK3203999T3 (da) 2020-03-30
ZA201702639B (en) 2018-06-27
PL3203999T3 (pl) 2020-07-27
UY36356A (es) 2016-06-01
US11185521B2 (en) 2021-11-30
AU2015330645B2 (en) 2020-03-12
PH12017500638A1 (en) 2017-09-25
JP6700639B2 (ja) 2020-05-27
AU2015330645A1 (en) 2017-05-04
CN106999456B (zh) 2020-07-10
SG11201702868VA (en) 2017-05-30
MX2017004733A (es) 2017-07-17
ES2785317T3 (es) 2020-10-06
CN106999456A (zh) 2017-08-01
JP2017530180A (ja) 2017-10-12
EP3203999A4 (en) 2018-06-27
EP3203999A1 (en) 2017-08-16
MX376873B (es) 2025-03-07
TWI699200B (zh) 2020-07-21
RU2017116178A3 (enExample) 2019-05-16
US20200237693A1 (en) 2020-07-30
US20180228750A1 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
US11185521B2 (en) Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
JP5371062B2 (ja) 代謝障害の処置のための化合物
CN104203901A (zh) 治疗炎症的组合物和方法
EA028535B1 (ru) Способы лечения с применением липидных соединений
JP2009502777A (ja) Ｐｐａｒ受容体及びｅｇｆ受容体に特異的な化合物及びそれらの塩並びに医療分野におけるそれらの使用
RU2712027C2 (ru) Соединения фенилкетонкарбоксилата и фармацевтические композиции для предотвращения и лечения остеопороза
TWI723967B (zh) 用於組織自修復及再生之經取代芳族化合物及醫藥組合物
HK1236420A1 (en) Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
HK1236420B (en) Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
US20110245528A1 (en) Therapeutic compounds
HK1236419A1 (en) Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
HK1236419B (en) Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
EP2822922B1 (en) Compound and its use for treating inflammation and modulating immune responses
PL233938B1 (pl) Pochodne kwasu 3-fenylo-4-heksynowego jako agoniści GPR40

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
PD4A Correction of name of patent owner